PE20090966A1 - Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2 - Google Patents

Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2

Info

Publication number
PE20090966A1
PE20090966A1 PE2008001762A PE2008001762A PE20090966A1 PE 20090966 A1 PE20090966 A1 PE 20090966A1 PE 2008001762 A PE2008001762 A PE 2008001762A PE 2008001762 A PE2008001762 A PE 2008001762A PE 20090966 A1 PE20090966 A1 PE 20090966A1
Authority
PE
Peru
Prior art keywords
antibody
bcl
active agent
type
combination therapy
Prior art date
Application number
PE2008001762A
Other languages
English (en)
Inventor
Thomas Friess
Christian Klein
Pamela Strein
Fernandez Pablo Umana
Original Assignee
Hoffmann La Roche
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38904707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Glycart Biotechnology Ag filed Critical Hoffmann La Roche
Publication of PE20090966A1 publication Critical patent/PE20090966A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE LA COMBINACION DE UN ANTICUERPO anti-CD20 DE TIPO II TAL COMO ANTICUERPO B-Ly1 HUMANIZADO Y UN AGENTE ACTIVO anti-Bcl-2C SELECCIONADO DE OBLIMERSEN, ABT-263, ABT-737, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION PARA UN KIT QUE LOS CONTENGA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE EL CD20 (ANTIGENO DE DIFERENCIACION RESTRINGIDA DEL LINFOCITO B HUMANO O Bp35) Y ES UTIL EN EL TRATAMIENTO DE LINFOMA DE CELULAS B NO DE HODGKIN
PE2008001762A 2007-10-15 2008-10-14 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2 PE20090966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07020120 2007-10-15

Publications (1)

Publication Number Publication Date
PE20090966A1 true PE20090966A1 (es) 2009-07-13

Family

ID=38904707

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001762A PE20090966A1 (es) 2007-10-15 2008-10-14 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2

Country Status (16)

Country Link
US (6) US20090098118A1 (es)
EP (2) EP2203185A1 (es)
JP (1) JP5416124B2 (es)
KR (1) KR101278395B1 (es)
CN (1) CN101827611B (es)
AR (1) AR068862A1 (es)
AU (1) AU2008314068B2 (es)
BR (1) BRPI0818673A2 (es)
CA (1) CA2702300A1 (es)
CL (1) CL2008003035A1 (es)
IL (1) IL204744A0 (es)
MX (1) MX2010003815A (es)
PE (1) PE20090966A1 (es)
RU (1) RU2541805C2 (es)
TW (1) TWI430809B (es)
WO (1) WO2009049841A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2380911T (lt) * 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
WO2008144506A1 (en) * 2007-05-16 2008-11-27 University Of Maryland, Baltimore Apoptotic pathway targeting for the diagnosis and treatment of cancer
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20190086591A (ko) * 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012021486A2 (en) * 2010-08-09 2012-02-16 University Of South Florida Acylsulfonamides and processes for producing the same
TW201209063A (en) 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
MX2013006739A (es) * 2010-12-16 2013-07-17 Roche Glycart Ag Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
KR101274731B1 (ko) * 2011-01-18 2013-06-18 동아대학교 산학협력단 레스베라트롤의 유사체인 ｈｓ－１７９３ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 하는 전립선 암 치료용 약학적 조성물
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN102222176A (zh) * 2011-06-01 2011-10-19 山东大学 一种快速发现以Bcl-2蛋白为靶点的先导化合物的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3919079A1 (en) 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
RU2727196C2 (ru) * 2015-05-26 2020-07-21 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе антитела к cd20 в сочетании с ингибитором bcl-2 и ингибитором mdm2
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3658584A1 (en) * 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
GEP20237460B (en) * 2018-07-31 2023-01-25 Ascentage Pharma Suzhou Co Ltd Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3983006A1 (en) 2019-06-12 2022-04-20 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2021264512A1 (en) * 2020-04-27 2022-11-17 Aruna Bio, Inc. Binding agents and uses thereof for central nervous system delivery
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US371191A (en) 1887-10-11 Cloth-sponging machine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0722342B1 (en) 1993-09-20 2004-12-29 The Trustees Of The University Of Pennsylvania REGULATION OF bcl-2 GENE EXPRESSION
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
KR20090088973A (ko) 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
AU2003300414A1 (en) 2002-12-19 2004-07-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
EP2264151B1 (en) 2003-01-22 2016-04-20 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
MXPA05012799A (es) 2003-05-30 2006-02-22 Gemin X Biotechnologies Inc Compuestos triheterociclicos, composiciones y metodos para tratar cancer o enfermedades virales.
CA2544368C (en) * 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
LT2380911T (lt) * 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
SG151299A1 (en) * 2004-03-25 2009-04-30 Univ Michigan Gossypol co-crystals and the use thereof
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006089397A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
TWI337608B (en) * 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
JP2008541758A (ja) * 2005-06-02 2008-11-27 アストラゼネカ エービー Ｃｄ２０に対する抗体およびその使用
CA2619298C (en) 2005-08-26 2017-07-04 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity

Also Published As

Publication number Publication date
EP2203185A1 (en) 2010-07-07
RU2010118448A (ru) 2012-05-20
US20090098118A1 (en) 2009-04-16
AU2008314068B2 (en) 2014-01-16
US20120276085A1 (en) 2012-11-01
AR068862A1 (es) 2009-12-09
JP5416124B2 (ja) 2014-02-12
EP2604277A1 (en) 2013-06-19
CL2008003035A1 (es) 2010-01-11
RU2541805C2 (ru) 2015-02-20
US20110287006A1 (en) 2011-11-24
BRPI0818673A2 (pt) 2015-09-08
IL204744A0 (en) 2010-11-30
JP2011500521A (ja) 2011-01-06
TW200920401A (en) 2009-05-16
CA2702300A1 (en) 2009-04-23
TWI430809B (zh) 2014-03-21
US20140004104A1 (en) 2014-01-02
US20110086025A1 (en) 2011-04-14
MX2010003815A (es) 2010-08-04
KR20100056559A (ko) 2010-05-27
CN101827611B (zh) 2014-01-15
US20150056186A1 (en) 2015-02-26
AU2008314068A1 (en) 2009-04-23
CN101827611A (zh) 2010-09-08
KR101278395B1 (ko) 2013-06-24
WO2009049841A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
PE20090966A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CL2013000685A1 (es) Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico.
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CR20140352A (es) Anticuerpo anti-epirregulina humanizado y agente terapéutico contra el cáncer que comprende dicho anticuerpo como ingrediente activo
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
PE20090975A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma
CL2012002733A1 (es) Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios.
AR084378A1 (es) Combinaciones de compuestos activos
TW200642836A (en) Radiation-absorbing materials, ophthalmic compositions containing same, and method of treating ophthalmic devices
PE20130826A1 (es) Trampa para mosquitos
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
UY31961A (es) "mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas"
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2008002798A1 (es) Compuestos heterociclicos nitrogenados que contienen (indol-3-il)alquil-1,4-diamin fenilo, inhibidores de la interaccion entre regulador negativo mdd2 y la proteina p53; proceso para su preparacion; composicion farmaceutica y combinacion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
AR094015A1 (es) Metodos para blanquear los dientes
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros

Legal Events

Date Code Title Description
FA Abandonment or withdrawal